BMJ 1994;308:868-869 (2 April)

Editorials

Tetrahydroaminoacridine and Alzheimer's disease

Tetrahydroaminoacridine (THA, tacrine), a cholinesterase inhibitor with several other actions that could enhance cognitive function,1 has passed the Food and Drug Administration's stringent licensing procedure for use in treating "mild to moderate" Alzheimer's disease.2

Since the first claim of its efficacy in Alzheimer's disease in a controlled trial in 19863 further studies have been almost equally divided between those reporting benefit for some patients with Alzheimer's disease and those reporting no benefit4 (such as the study by Maltby in this issue p 8795). No washout period or inadequate outcome measures are apparent in most studies, and comparison between them is also complicated by the concurrent use of lecithin in some studies. The dosage of tetrahydroaminoacridine varies widely, between 20 mg and 114 mg a day, as does the duration of treatment, from one to 13 weeks. The studies also report high rates of adverse effects, the commonest being hepatoxicity . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Pendlebury, W W, Solomon, P R, Levy, R, Roberts, C, Makela, P, Ford, J, Truman, C, Wilcock, G K, Broe, G A, Creasey, H, Maltby, N, Grayson, D A (1994). Tacrine and lecithin in Alzheimer's disease Tacrine is safe and effective. BMJ 308: 1506-1507 [Full text]  
  • (1994). TACRINE AND ALZHEIMER'S: THERE'S STILL MORE TO LEARN. JWatch General 1994: 5-5 [Full text]  
Access jobs at BMJ Careers
Whats new online at Student BMJ